More Related Content Similar to Gastroenterology - 01. Gastroesophageal Reflux Disease (Courses in Therapeutics and Disease State Management).ppt (20) Gastroenterology - 01. Gastroesophageal Reflux Disease (Courses in Therapeutics and Disease State Management).ppt1. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Gastroenterology:
Gastroesophageal Reflux Disease
Courses in Therapeutics and Disease State Management
2. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Learning Objectives (Slide 1 of 2)
• Define GERD and describe the various stages of disease severity
• Describe the etiology of GERD and risk factors associated with
the disease
• Discuss typical symptoms, atypical symptoms, alarm symptoms,
aggravating factors and complications associated with GERD
• Describe how GERD is diagnosed and the role of endoscopy
• Discuss the various pharmacologic approaches for the treatment
of GERD
3. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Learning Objectives (Slide 2 of 2)
• Review the roles of the H2-antagonists and proton pump inhibitors
in the treatment of GERD and prevention of its recurrence
• Describe non-pharmacologic and lifestyle measures that may be
beneficial in the reduction of symptoms of reflux disease
• Given a GERD patient history, be able to recommend appropriate
pharmacologic and nonpharmacologic therapies and explain the
rationale behind your decision
• Discuss drug adverse effects and monitoring parameters for drugs
and GERD
4. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Required and Recommended Reading
May D, Thiman M, Rao SC. Gastroesophageal Reflux
Disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR,
Wells BG, Posey L. eds. Pharmacotherapy: A
Pathophysiologic Approach, 10e New York, NY: McGraw-
Hill; 2017.
5. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
GERD Definitions
• GERD (Gastroesophageal Reflux Disease)
– A condition that occurs when refluxed stomach contents lead to troublesome symptoms
and/or complications
– Episodic pyrosis (heartburn) that is not frequent enough or painful enough to be
considered bothersome by the patient is not included in the above consensus GERD
definition
• Pyrosis frequency of more than 2 times per week is sometimes used as a criteria for GERD
• Chronic symptoms or mucosal damage produced by the abnormal reflux of gastric
contents into the esophagus.
• Symptoms of GERD vary in severity, duration, and frequency.
• When the esophagus is repeatedly exposed to refluxed material for prolonged
periods of time, inflammation of the esophagus (esophagitis) occurs, and in some
cases it can progress to erosion of the squamous epithelium of the esophagus
(erosive esophagitis) and may lead to other complications.
6. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Epidemiology (Slide 1 of 2)
• Heartburn is the most frequent clinical complaint
– Reported to occur at least once daily in 10%
– 20% weekly;
– 44% monthly of U.S. adults
– $5 billion for OTC/Rx per year
• Most frequently occurs in adults over 40 years of age
• Incidence in similar between men and women
7. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Epidemiology (Slide 2 of 2)
• About 50% of pregnant women will experience GERD
• Can also occur in infants
• Prevalence depends on geographic region but is highest
in Western countries
8. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Risk Factors
• Obesity (BMI ≥ 30)
• Alcohol use
• Smoking
• Excessive caffeine intake
• Respiratory diseases
9. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Key Factors in the Development of GERD
(Slide 1 of 2)
• A decrease in lower esophageal sphincter (LES) pressure
• Decreased clearance of gastric contents from the
esophagus
• Decreased mucosal resistance in the esophagus
10. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Key Factors in the Development of GERD
(Slide 2 of 2)
• Composition of reflux contents “extra acidic”
– Gastric fluid that has a pH < 4 is extremely caustic to the
esophageal mucosa.
• Decreased gastric emptying (increased gastric emptying
time)
• Certain anatomic features
– Most commonly a hiatal hernia
11. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Pathophysiology of GERD (Role of the Lower
Esophageal Sphincter)
• Link: Figure of comparison of esophageal high-resolution
manometry
• Link: Figure of pathophysiology of esophageal reflux
disease (LES, lower esophageal sphincter)
12. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Hiatal Hernia
• A hiatal hernia occurs when a portion of the stomach
protrudes through the diaphragm into the chest
– Causes a disruption in the normal anatomic barriers between
the stomach and the esophagus
• Link: Figure of radiographic anatomy of the
gastroesophageal junction
13. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
GERD Symptoms
• GERD symptoms are often grouped in 3 categories
– Typical or “classic” esophageal symptoms
– Alarm or complicated symptoms
• May be indicative of GERD complications
– Atypical or extraesophageal symptoms
14. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Typical or “Classic” Symptoms
• Pyrosis (heartburn)
– Hallmark symptom
– A substernal feeling of warmth or burning rising up from the
abdomen that may radiate to the neck
• Regurgitation/Belching
• Acid brash/Hypersalivation
• Chest pain (non cardiac in nature)
15. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Alarm (Complicated) Symptoms
• Any of these symptoms warrant immediate referral for
testing
– Dysphagia
– Odynophagia
– Bleeding
– Unexplained weight loss
– Choking
– Chest pain (if could be cardiac in nature)
16. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Extraesophageal Symptoms/Manifestations (Atypical
Symptoms)
• These symptoms have an association with GERD but
causality should only be considered if a concomitant
esophageal symptoms are present
– Chronic cough
– Asthma-like symptoms
• About 50% of those with asthma have GERD
– Laryngitis/Hoarseness
– Recurrent sore throat
– Dental enamel erosion
17. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
GERD
• GERD is often described on either esophageal symptoms or
esophageal tissue injury
– Symptom-based GERD syndromes (with or without esophageal
tissue injury)
– Tissue injury-based GERD syndromes (with or without esophageal
symptoms)
• Extraesophageal GERD syndromes may also occur
• GERD is also sometimes described in terms of the absence
or presence of esophageal erosions
– Non-erosive reflux disease (NERD)
– Erosive reflux disease (ERD)
18. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Symptom-Based GERD Syndromes
• May or may not have esophageal tissue injury
• Have typical or “classic” esophageal symptoms
• May have alarm symptoms particularly if GERD
complications (see next section) are present
19. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Tissue-Injury Based GERD Syndromes
• Examples of esophageal tissue injury include the presence of
any of the following:
– Esophagitis (inflammation of the esophagus)
– Erosions (erosion of the squamous epithelium of the esophagus)
– Strictures
– Barrett’s esophagus
– Esophageal adenocarcinoma
• May present with alarm symptoms particularly if have GERD
complications
• May or may not have typical or classic symptoms
20. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Extraesophageal GERD Syndromes
• Present with extraesophageal or atypical symptoms
• May or may not have typical esophageal symptoms
• Extraesophageal symptoms have an association with GERD,
but causality should only be considered if a concomitant
esophageal GERD syndrome is also present
• Extraesophageal manifestations of GERD are being
recognized with increasing frequency.
• GERD may be either a causative or exacerbating factor in up
to 50% of patients who experience these symptoms.
21. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Aggravating Factors
• Recumbency
• Increased intra-abdominal pressure
• Reduced gastric motility
• Decreased LES tone or pressure
• Direct mucosal irritation
22. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Decrease in LES Pressure
• Examples of foods that decrease LES pressure
– Fatty foods, peppermint, spearmint, chocolate, coffee, cola, tea,
garlic, onions, chili peppers
• Examples of medications that decrease LES pressure
– Anticholinergics, barbiturates, benzodiazepines, caffeine,
dihydropyridine calcium channel blockers, dopamine, estrogen,
ethanol, narcotics, nicotine, nitrates, progesterone, theophylline
23. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Direct Mucosal Irritation
• Examples of foods that are direct irritants to the
esophageal mucosa
– Spicy foods, orange juice, tomato juice, coffee
• Examples of medications that are direct irritants to the
esophageal mucosa
– Oral bisphosphonates, aspirin, iron, NSAIDs, quinidine,
potassium
24. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Foods and Medications that May Worsen GERD Symptoms
Foods/Beverages Medications
Decreased Lower Esophageal Sphincter Pressure
Fatty meal Anticholinergics
Carminatives (peppermint, spearmint) Barbiturates
Chocolate Caffeine
Coffee, cola, tea Dihydropyridine calcium channel blockers
Garlic Dopamine
Onions Estrogen
Chili peppers Nicotine
Alcohol (wine) Nitrates
Progesterone
Tetracycline
Theophylline
Direct Irritants to the Esophageal Mucosa
Spicy foods Aspirin
Orange juice Bisphosphonates
Tomato juice Nonsteroidal antiinflammatory drugs (NSAIDs)
Coffee Iron
Tobacco Quinidine
Potassium chloride
25. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Complications of GERD
• Esophagitis
– Link: Figure of EGD demonstrating linear red streaks with a central
white streak extended up the esophagus in peptic regurgitant
esophagitis
• Erosions and ulceration of the esophageal mucosa
• Strictures of the esophagus
– Secondary to fibrous tissue deposition after long standing erosion
• Barrett’s esophagus
– Present in about 10% of those with GERD
– Most prevalent in white males in Western countries
• Esophageal adenocarcinoma
26. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Barrett’s Esophagus (Slide 1 of 2)
• Barrett’s esophagus occurs when the normal squamous
cell epithelium in the esophagus converts to a columnar
cell epithelium (intestinal-type epithelium)
• More common in men than women
• Barrett’s esophagus does not cause specific symptoms
but the reflux does
27. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Barrett’s Esophagus (Slide 2 of 2)
• Those with Barrett’s esophagus develop adenocarcinoma
of the esophagus at a rate of 0.12% per year
– Gender ratio for esophageal adenocarcinoma is 8:1
(male:female)
• Patients must be monitored via endoscopy to evaluate
changes in cell type and conversion to adenocarcinoma
28. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Complications of GERD (Photos)
Link: Photos of endoscopic appearance of peptic
esophagitis, a peptic stricture, Barrett’s metaplasia, and
adenocarcinoma
29. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
GERD Diagnosis/Diagnostic Tests (Slide 1 of 4)
• Clinical History
– Patient’s description of typical or classic GERD symptoms such
as pyrosis, is often enough to consider GERD as an initial
diagnosis (uncomplicated GERD)
• Empiric trial of proton pump inhibitor (PPI) therapy
– ACG (American College of Gastroenterology) guidelines state
that it is reasonable to assume a GERD diagnosis in patients
who respond to appropriate therapy
30. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
GERD Diagnosis/Diagnostic Tests (Slide 2 of 4)
• Endoscopy
– Endoscopy is the technique of choice to identify complications of
GERD such as ulcerations, erosions, Barrett’s esophagus, etc.
– Biopsy of the esophageal tissue is needed to identify and diagnose
Barrett’s esophagus and esophageal adenocarcinoma
– Many patients with GERD (presenting with typical or atypical
symptoms) will have normal appearing esophageal mucosa on
endoscopy
– Usually not part of the work-up except in certain subsets of patients
(alarm symptoms, those refractory to treatment, etc.)
31. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
GERD Diagnosis/Diagnostic Tests (Slide 3 of 4)
• Ambulatory pH Monitoring
– Identifies patients with excessive esophageal acid exposure
and helps determine if symptoms are acid related
– Useful in patients not responding to acid-suppression therapy
• Barium Radiography
– Not routinely used to diagnose GERD due to a lack of
sensitivity and specificity
– Can detect hiatal hernia
32. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
GERD Diagnosis/Diagnostic Tests (Slide 4 of 4)
• Patients presenting with extraesophageal or atypical
symptoms should be reviewed on a case-by-case basis to
be considered for testing
• Alarm symptoms always warrant further testing
33. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Therapeutic Approach to GERD
• The initial treatment used is determined by the patient’s
condition:
– Frequency of symptoms
– Degree of symptoms
– Presence and/or degree of esophagitis
– Presence of complications
34. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Goals of Treatment
• Alleviate or eliminate acute symptoms
• Decrease frequency of recurrence
• Promote healing if esophageal tissue injury is present
• Prevent complications
35. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
General Treatment Approach
• Initial therapy in patients who present with typical GERD symptoms
should include patient-directed (self-care) therapy (antacids, OTC
H2-antagonist, or OTC PPIs) and lifestyle modifications
• Those who do not respond to patient-directed therapy and lifestyle
modifications after 2 weeks should seek medical attention and are
usually started on empiric therapy consisting of an acid suppression
agent such as a proton pump inhibitor (PPI)
• Those who do not respond to empiric acid suppression therapy or
have alarm symptoms should undergo testing such as an endoscopy
36. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Nonpharmacologic Therapies
• Lifestyle modifications
– Should be incorporated into the management of GERD regardless of the
severity of disease
– Lifestyle modifications should be tailored to an each individual patient’s
needs
• Anti-reflux surgery
– Used as a last resort option in select patients
• When long-term pharmacologic therapy is undesirable
• Who have refractory GERD
• Have complications
• Endoscopic therapies
– Results have been disappointing and hence are not usually recommended
37. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Lifestyle Modifications (Slide 1 of 2)
• Weight loss (if the patient is overweight or obese)
• Elevation of the head of the bed 6 to 8 inches
• Eat smaller, more frequent meals (as opposed to larger
meals less frequently)
• Include protein-rich meals in diet (increases LES
pressure)
38. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Lifestyle Modifications (Slide 2 of 2)
• Avoid eating 3 hours prior to sleeping or lying down
• Avoid foods or medications that exacerbate GERD
• Avoid alcohol
• Tobacco cessation
39. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Endoscopic Interventions
• Stretta Procedure
– Stretta is an endoscopically guided radiofrequency (RF) energy delivery
system. The device is guided down the esophagus and RF energy is
delivered to tissues via catheters/needles. RF energy is thought to
improve GERD symptoms by increasing collagen deposition at the LES,
increasing muscle wall thickness and reconstituting the barrier to the
reflux of gastric contents.
• LINX Reflux Management System (FDA approved March 2012)
– A series of titanium beads each with a magnetic core connected together
with a wire to form a ring shape.
– Implanted in the LES
– The force of the magnetic beads provides additional strength to a keep a
weak LES closed.
40. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Therapeutic Interventions in the Management
of GERD
Link: Figure of therapeutic interventions in the
management of gastroesophageal reflux disease
41. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Pharmacologic Agents Used in the Treatment of
GERD
• Antacids and alginic acid products
• H2-receptor antagonists (HRA)
• Proton pump inhibitors (PPIs)
• Promotility agents
42. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Antacids (Slide 1 of 2)
• MOA
– Neutralize hydrochloric acid in the stomach, which results in an increase
in gastric pH
• Agents
– Magnesium hydroxide
– Aluminum hydroxide
– Calcium carbonate
• Adverse effects
– Diarrhea (magnesium hydroxide)
– Constipation (aluminum hydroxide and calcium carbonate)
– Alterations in mineral metabolism
– Acid-base disturbances
43. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Antacids (Slide 2 of 2)
• Monitoring
– Periodic calcium and phosphate levels if on chronic antacid therapy
• Patient counseling
– Antacids can decrease the levels of numerous other drugs including
tetracyclines, digoxin, iron supplements, fluroquinolones, and
ketoconazole.
• Patients should separate antacids and other medications by at least 2 hours
– Patients with renal impairment should not use aluminum or
magnesium containing antacids unless directed by their physician
– Onset of relief is less than 5 minutes and duration of relief is 20 to
30 minutes
44. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Composition and Acid Neutralizing Capacities of Popular Antacid Preparations
PRODUCT Al(OH)3
a Mg(OH)2
a CaCO3
a SIMETHICONEa ACID NEUTRALIZING
CAPACITYb
Tablets
Gelusil 200 200 0 25 10.5
Maalox Quick Dissolve 0 0 600 0 12
Mylanta Double Strength 400 400 0 40 23
Riopan Plus Double
Strength
Magaldrate, 1080 20 30
Calcium Rich Rolaids 80 412 0 11
Tums EX 0 0 750 0 15
Liquids
Maalox TC 600 300 0 0 28
Milk of Magnesia 0 400 0 0 14
Mylanta Maximum
Strength
400 400 0 40 25
Riopan Magaldrate, 540 0 15
aContents, milligrams per tablet or per 5 ml.
bAcid neutralizing capacity, milliequivalents per tablet or per 5 ml.
The U.S. marketplace for antacids is fluid. The current trend of "reusing" well-known brand names to introduce new products that contain an active ingredient different from expected is a source of confusion that can
present a danger to patients. Medication safety experts encourage clinical practitioners to refer to the active ingredient(s) in conjunction with the proprietary (brand) name when selecting OTC products.
45. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Antacid-Alginic Acid Combination
• MOA
– The antacid neutralizes stomach acid and the alginic acid is a
foaming agent that creates a viscous solution that floats on top
of the stomach contents and may be protect the esophagus
from refluxed stomach acid
• Agents
– Aluminum hydroxide/Magnesium carbonate/Alginic acid
(Gaviscon)
46. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
H2-Receptor Antagonists (Slide 1 of 2)
• MOA
– Competitive inhibition of histamine at H2 receptors of gastric
parietal cells which inhibits gastric acid secretion
• Agents
– Cimetidine (Tagamet)
– Famotidine (Pepcid)
– Nizatidine (Axid)
– Ranitidine (Zantac)
47. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
H2-Receptor Antagonists (Slide 2 of 2)
• Adverse effects
– Headache, somnolence, fatigue, dizziness, constipation, diarrhea
• Monitoring
– Monitor for CNS effects (rare) in those over 50 years old or in those
with renal or hepatic impairment
• Patient counseling
– If taking once a day, it is preferable to take the dose at bedtime
– Onset of relief is 30 to 45 minutes and duration of relief is 4 to 10
hours
48. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Proton Pump Inhibitors (PPIs) (Slide 1 of 3)
• MOA
– Blocks acid secretion by inhibiting gastric H+/K+ adenosine triphosphatase found
on the secretory surface of gastric parietal cells
– Results in a long-lasting anti-secretory effect that can maintain gastric pH levels
above 4
• Agents
– Dexlansoprazole (Dexilant)
– Esomeprazole (Nexium)
– Lansoprazole (Prevacid)
– Omeprazole (Prilosec)
– Omeprazole/sodium bicarbonate (Zegerid)
– Pantoprazole (Protonix)
– Rabeprazole (Aciphex)
49. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Proton Pump Inhibitors (PPIs) (Slide 2 of 3)
• Common adverse effects
– Headache, dizziness, somnolence, diarrhea, constipation,
flatulence, abdominal pain, nausea
• Serious adverse effects
– Increased risk of Clostridium difficile infections
– Increase risk of community-acquired pneumonia
• Long-term adverse effects (> 1 year)
– Hypomagnesemia
– Bone fractures
– Vitamin B12 deficiency
50. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Proton Pump Inhibitors (PPIs) (Slide 3 of 3)
• Monitoring
– Appearance of diarrhea (frequency and type of diarrhea episodes)
– Periodic magnesium levels (if long-term therapy)
– Routine bone density studies (DXA scans)
• If other risk factors for osteoporosis or bone fractures present
• Patient counseling
– Preferable to take a PPI 30 to 60 minutes before a meal (mainly
breakfast)
– If a second dose is needed, take prior to the evening meal
– Onset of relief is 2 to 3 hours and the duration of relief is 12 to 24
hours
51. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Evaluate the Risks versus Benefits of
Long-Term PPI Use (Slide 1 of 2)
• Long-term PPI use has been associated with increased
risk of:
– Fractures
– Infections such as C. Diff and pneumonia (expand)
– Hypomagnesemia
– Vitamin B12 deficiency
52. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Evaluate the Risks versus Benefits of
Long-Term PPI Use (Slide 2 of 2)
• Long-term PPI use MAY BE associated with increased
risk of:
– Dementia
– Renal disease
– Cardiovascular disease
53. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Promotility Agents
• Promotility agents, such as metoclopramide and
bethanechol, have been used as adjunct therapy to acid
suppression agents such as PPIs in patients who have a
known motility defect
• However, they are not generally recommended to be used
for GERD treatment due to their limited effectiveness and
undesirable adverse effect profiles
54. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Pharmacologic Therapy (Slide 1 of 3)
• Patient directed therapy (Self-care) is appropriate for
intermittent, mild pyrosis and is managed using over-the-
counter products such as antacids, OTC H2-receptor
antagonists, and OTC proton pump inhibitors (PPIs)
• Link: Table on Therapeutic Approach to GERD in Adults
55. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Pharmacologic Therapy (Slide 2 of 3)
• Symptomatic relief of uncomplicated GERD is treated with
prescription H2-receptor antagonists or prescription PPIs
at the following doses and durations:
• Refer to Link: Table on Therapeutic Approach to GERD
in Adults
56. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Pharmacologic Treatment (Slide 3 of 3)
• Healing of erosive esophagitis or treatment of patients
presenting with moderate to severe symptoms or
complications
• Refer to Link: Table on Therapeutic Approach to GERD
in Adults
57. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
PPIs v. H2-Receptor Antagonists
• Symptomatic improvement as well as endoscopic healing
rates are higher for the PPIs compared to the H2-receptor
antagonists
• PPIs are therefore preferred over H2-receptor antagonists
in patients with erosive disease, moderate to severe
symptoms, or with complications
58. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Maintenance Therapy (Slide 1 of 2)
• What patients should receive maintenance therapy?
– Those with symptomatic relapse following discontinuation of the
drug or a decrease in dose.
• If NERD/uncomplicated GERD, try to manage with on-demand or
intermittent PPI therapy or H2-receptor antagonists
59. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Maintenance Therapy (Slide 2 of 2)
• What patients should receive maintenance therapy?
– Those with a history of complications (e.g. Barrett’s esophagus,
strictures, hemorrhage, ulcerations, etc.)
• Long-term maintenance therapy with PPIs at the lowest possible dose
– Can consider intermittent or on demand PPI therapy in some circumstances
60. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
PPIs and Rebound Acid Secretion (Slide 1 of 2)
• There have been reports of rebound acid secretion when
PPIs are abruptly discontinued.
– This can happen when PPIs are used for as little as 2 months
(and of course when they are used longer)
– These hyperacidity symptoms include dyspepsia and heartburn
• Often attributed to a relapse of the disorder (e.g. GERD), but it can
even happen in patients who didn’t have these symptoms to start with
61. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
PPIs and Rebound Acid Secretion (Slide 2 of 2)
• Tapering strategies for patients experiencing rebound acid
secretion
– (1) Taper PPI over 4 to 6 weeks
• First lower the dose of the PPI
• Then extend the PPI dosing interval to every other day then every 3rd
day
• An H2-antagonist or antacid can be used for symptoms on “off days” as
needed
– (2) Suggest a switch to an H2-antagonist with antacids used as
needed for several weeks then discontinue
62. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Patients with Extraesophageal (Atypical) GERD
(Slide 1 of 2)
• GERD can be considered as a potential co-factor in
patients with asthma, chronic cough, or laryngitis
– Careful evaluation of non-GERD causes should be undertaken
in all of these patients
• Patients with atypical symptoms may need higher doses
of acid suppression therapy with longer treatment duration
compared to those patients with typical symptoms
63. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Patients with Extraesophageal (Atypical) GERD
(Slide 2 of 2)
• A PPI trial is recommended to treat extraesophageal
symptoms in patients who have typical GERD symptoms
as well
• Reflux monitoring should be considered before a PPI trial
in patients with extraesophageal symptoms who do not
have typical GERD symptoms
64. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Pediatric Patients (Slide 1 of 2)
• A suspected cause of reflux in infants is a
developmentally immature LES
• Many infants have reflux with little or no clinical
consequence
– This uncomplicated reflux usually manifests as regurgitation or
spitting up
– Usually responds to supportive therapy
• Chronic vomiting associated with GERD must be carefully
evaluated and distinguished from other causes
65. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Pediatric Patients
• Careful consideration should be given before a medication is
recommended
• When a medication is deemed necessary, ranitidine dosed at
2 to 4mg/kg twice a day is often used
• PPIs are increasing being used in children older than 1 year
– Lansoprazole, esomeprazole, and omeprazole are indicated for
treating symptomatic and erosive GERD in children > 1 year old
– See next slide for dosing ranges
• Omeprazole has been used off-label in children less than 1
year old at a dose of 1mg/kg/day
66. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
PPIs in Children > 1 year of age
• Lansoprazole
– 15mg per day is recommended for children weighing < 30kg
– 30mg per day is recommended for children weighing > 30kg
• Esomeprazole
– Dosed 10 to 20mg a day for children 1 to 11 years old
– Dosed at 20 to 40mg a day for children 12 to 17 years old
• Omeprazole
– 5mg daily in children weighing between 5 and 10kg
– 10mg daily in children weighing between 10 and 20kg
– 20mg daily in children weighing ≥ 20kg
67. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Elderly Patients
• Many elderly patients have decreased defense
mechanisms such as decreased saliva production
• PPI therapy may be warranted for those > 60 years of age
with symptomatic GERD
– They have superior efficacy and have once a day dosing
– Long-term risk of bone fractures is a concern and elderly
patients should be monitored appropriately
• Elderly are at higher risk of being sensitive to possible
CNS effects of H2-receptor antagonists
68. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
Patients with Refractory GERD
• Refractory GERD should be considered in patients who have
not responded to a standard course of twice a day PPI
therapy
• The majority of patients with refractory symptoms experience
nocturnal acid breakthrough
• Switching to a different PPI may be effective in some patients
• Adding an H2-receptor antagonist at bedtime for nocturnal
symptoms is reasonable but the effect may decrease over
time due to tachyphylaxis with H2-receptor antagonists
69. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
References (Slide 1 of 3)
• May D, Thiman M, Rao SC. Gastroesophageal Reflux
Disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG,
Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach,
10e New York, NY: McGraw-Hill; 2017.
• Mills JC, Stappenbeck TS. Gastrointestinal Disease. In: Hammer
GD, McPhee SJ. eds. Pathophysiology of Disease: An Introduction
to Clinical Medicine, Seventh Edition. New York, NY: McGraw-Hill;
2013.
• Kahrilas PJ, Hirano I. Diseases of the Esophagus. In: Kasper D,
Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Harrison's
Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill;
2015.
70. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
References (Slide 2 of 3)
• Wallace JL, Sharkey KA. Pharmacotherapy of Gastric Acidity,
Peptic Ulcers, and Gastroesophageal Reflux Disease. In:
Brunton LL, Chabner BA, Knollmann BC. eds. Goodman &
Gilman's: The Pharmacological Basis of Therapeutics, 12e.
New York, NY: McGraw-Hill; 2011.
• Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis
and management of gastroesophageal reflux disease. Am J
Gastroenterol 2013; 108: 308-328.
• Schoenfeld AJ, Grady D. Adverse effects associated with
proton pump inhibitors. JAMA Internal Medicine 2016; 176(2):
172-174.
71. Author: Monica L. Skomo, B.S., Pharm.D., BCACP, CTTS; Assoc. Prof. of Pharmacy Practice; Dir. of Assessment and Educational Strategies; Duquesne University School of Pharmacy
http://accesspharmacy.mhmedical.com/LearningModuleGroup.aspx?id=8
Copyright © 2017 McGraw-Hill Education. All rights reserved
References (Slide 3 of 3)
• Micromedex Solutions. Truven Health Analytics, Inc. Ann
Arbor, MI. Accessed October 15, 2016.
• Lexicomp Online®, Lexi-Drugs®, Hudson, Ohio: Lexi-
Comp, Inc. Accessed October 15, 2016.
Editor's Notes Each one of the following patients is presenting with the same signs and symptoms consistent an infection. If symptoms (e.g. pyrosis) are not frequent or troublesome, it is usually not considered to be gastroesophageal reflux disease (GERD).
Many people experience occasional pyrosis (heartburn) - It can occur in all ages, but most frequently in adults over 40 years old Pregnancy causes an increase in intra-abdominal pressure particularly in the 3rd trimester
Infants have lesser developed lower esophageal sphincters and are frequently in a recumbent position, both of which increase their risk of GERD Obese patients are 3 times more likely to develop GERD than non-obese patients
Ethanol decreases lower esophageal sphincter pressure causing it to relax.
Nicotine decreases lower esophageal sphincter pressure causing it to relax.
Caffeine decreases lower esophageal sphincter pressure causing it to relax.
- Decreased clearance can happen due to decreased esophageal peristalsis and/or decreased salivary production. Salivary flow down the esophagus helps to clear gastric contents. Also, saliva contains bicarbonate which helps to buffer gastric contents.
- Examples of decreased mucosal resistance include decreased mucous production and decreased bicarbonate secretion Delayed gastric empyting can occur when there is a high gastric volume and a decreased gastric emptying rate. For example, fatty foods can increase gastric volume and decrease gastric emptying rate. In addition, fatty foods can decrease LES pressure.
GERD is often described and classified in multiple ways. First is by symptoms, which is discussed in the next several slides.
GERD is also described if tissue injury is present (erosive disease) or absent (non-erosive disease). This is also discussed in later slides. If a patient gets occasional pyrosis, they do not necessarily have GERD. Many people get heartburn occasionally. - Not everyone with tissue injury from reflux will present with the “classic” symptoms such as pyrosis. There are many situations that can aggravate GERD symptoms. Avoiding situations, medications, food, etc. that exacerbate symptoms is common and important strategy in GERD management.
Common things that can increase intra-abdominal pressure include obesity, pregnancy, tight clothing, belts, bending over)
There are multiple foods and medications that can decrease LES tone or pressure
There are multiple foods and medications that are direct irritants to the esophageal mucosa - There are a variety of foods and medications that can decrease LES pressure and hence aggravate or exacerbate GERD symptoms such as pyrosis. - There are foods and medications that are very irritating to the esophageal mucosa and hence can exacerbate pyrosis From AccessPharmacy: accesspharmacy.mhmedical.com, Copyright© McGraw-Hill Education. All rights reserved.
Chapter 19. Antimicrobial Regimen Selection, Table 19-1 Foods and Medications that May Worsen GERD SymptomsPharmacotherapy: A Pathophysiologic Approach, 9e, 2014
Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey
Erosions and ulcerations may have bleeding. The blood loss is usually low grade and chronic in nature and may lead to anemia
Strictures of the esophagus are most common in the distal esophagus. They are usually 1 to 2 cm in length.
Barrett’s esophagus may occur after long-standing disease
About 1/3 of those with Barrett’s esophagus have minimal or no symptoms - The frequency of endoscopy depends on biopsy results. - Invasive testing such as endoscopy is not necessary in these circumstances - Many patients with GERD (presenting with typical or atypical symptoms) will have normal appearing esophageal mucosa on endoscopy. That doesn’t mean they don’t have GERD. It means at that point in time they do not have any esophageal tissue injury present.
- OTC = over the counter or nonprescription medications Endoscopic therapies include endoscopic sewing devices, the Stretta procedure, and the LINX system. - To elevate the head of the bed, it is preferable to place a wedge or blocks between the mattress and the box spring as opposed to stacking pillows under the patient’s head - Remember both alcohol and nicotine decrease LES pressure and can exacerbate symptoms - Antacids can interact and decrease the effectiveness of other medications through a various mechanisms including increasing gastric pH with resulting decreased absorption of some medications, increasing urinary pH, adsorbing other medications, acting as a physical barrier to the absorption of other medications, forming insoluble complexes with some medications. From AccessPharmacy: accesspharmacy.mhmedical.com, Copyright© McGraw-Hill Education. All rights reserved.
Chapter 45: Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease
Table 45-2Composition and Acid Neutralizing Capacities of Popular Antacid Preparations
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e, Copyright © 2011
Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann - There is a correlation between the percentage of time that the gastric pH remains above 4 and healing of erosive esophagitis. - Rebound acid secretion following discontinue of a PPI as described could be one reason why some people find it hard to stop a PPI - Either of these 2 strategies is appropriate to use to successfully discontinue a PPI in a patient who is experiencing rebound acid secretion symptoms after discontinuing a PPI - Supportive therapy includes dietary adjustments, postural management, thickened feedings